New pill combo aims to prevent return of early breast cancer
NCT ID NCT04296162
First seen May 29, 2026 · Last updated Jun 20, 2026 · Updated 6 times
Summary
This study tested whether taking oral chemotherapy pills (vinorelbine or capecitabine) along with the targeted drug trastuzumab can help prevent breast cancer from coming back in women with small, HER2-positive tumors that have not spread to lymph nodes. The 182 participants took the combination after surgery. The goal was to see how long they stayed cancer-free, with a focus on safety and convenience of oral treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhi-Ming Shao
Shanghai, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral vinorelbine or capecitabine combined with trastuzumab
What this could lead to
If successful, this could offer a more convenient oral chemotherapy option alongside targeted therapy for early-stage HER2-positive breast cancer, potentially reducing recurrence risk.
What could go wrong
This is a Phase II trial with only 182 participants, so results are preliminary. The combination may not improve outcomes over standard care, and side effects from chemotherapy and trastuzumab (e.g., heart issues, fatigue) remain concerns.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.